Search results for "Intention to Treat Analysis"

showing 10 items of 27 documents

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

Hepatocellular carcinoma in Child's A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection accord…

2013

This is the first matched pair analysis on the puzzling clinical problem of whether to perform liver transplantation (LT) or liver resection (LR) for Child's A hepatocellular carcinoma (HCC) patients. A total of 201 patients diagnosed with HCC and Child's A liver cirrhosis were treated with LT transarterial chemoembolization (TACE) or LR between 1998 and 2012. To achieve the most accurate study design, two groups of 57 patients were matched retrospectively according to their tumor characteristics detected by the initial computerized tomography (CT) scan. Sixteen of 57 LT candidates were not transplanted due to tumor progress during pre-treatment (TACE). Nevertheless, the retrospective analy…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentMatched-Pair AnalysisMilan criteriaLiver transplantationGastroenterologyResectionRecurrenceInternal medicinemedicineRetrospective analysisHepatectomyHumansIn patientAgedRetrospective StudiesAged 80 and overTransplantationIntention-to-treat analysisbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisIntention to Treat AnalysisLiver TransplantationSurvival RateHepatocellular carcinomaFemalebusinessFollow-Up StudiesClinical transplantation
researchProduct

Virtual reality versus computer-aided exposure treatments for fear of flying

2011

Evidence is growing that two modalities of computer-based exposure therapies—virtual reality and computer-aided psychotherapy—are effective in treating anxiety disorders, including fear of flying. However, they have not yet been directly compared. The aim of this study was to analyze the efficacy of three computer-based exposure treatments for fear of flying: virtual reality exposure therapy (VRET), computer-aided exposure with a therapist’s (CAE-T) assistance throughout exposure sessions, and self-administered computer-aided exposure (CAE-SA). A total of 60 participants with flying phobia were randomly assigned to VRET, CAE-T, or CAE-SA. Results indicate that the three interventions were …

AdultMaleAircraftPsychological interventionImplosive TherapyFlying PhobiaStatistics NonparametricVirtual realitylaw.inventionExposureFear of flyingVirtual Reality Exposure TherapyUser-Computer InterfaceArts and Humanities (miscellaneous)Randomized controlled trialFear of flyinglawDevelopmental and Educational PsychologymedicineHumansComputer SimulationAnalysis of VarianceIntention-to-treat analysisModalitiesfungiPor a volar--Tractament--Simulació per ordinadorFearMiddle Agedmedicine.diseaseFear of flying --Treatment--Computer simulationIntention to Treat AnalysisTreatmentClinical PsychologyTreatment OutcomePhobic DisordersComputer-aidedPatient SatisfactionRandomized controlled trialTherapy Computer-AssistedAnxietyFemalemedicine.symptomPsychologyClinical psychology
researchProduct

Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.

2021

INTRODUCTION: We assessed the performance of direct-acting antivirals (DAAs) in hepatitis C virus (HCV)-infected people who use drugs (PWUDs) in terms of sustained virological response (SVR) and adherence rates in comparison to a location-matched cohort of non-PWUD HCV patients. METHODS: All consecutive HCV RNA-positive PWUDs were enrolled between 2015 and 2019. All subjects underwent DAA treatment according to international guidelines and then followed, at least, up to 12 weeks after the end of treatment (SVR12). The SVR and adherence to treatment was compared with that of non-PWUD HCV patients observed at hepatological units of the CLEO platform. Intention-to-treat analysis was performed.…

AdultMaleElbasvirmedicine.medical_specialtySofosbuvirSustained Virologic ResponseIntention to Treat AnalysiSubstance-Related DisordersHepatitis C virusmedicine.disease_causeAntiviral AgentsMedication Adherence03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansProspective StudiesRetrospective StudiesAntiviral AgentHepatologybusiness.industryGastroenterologyvirus diseasesGlecaprevirOdds ratioHepatitis C ChronicMiddle AgedSubstance-Related DisorderPibrentasvirdigestive system diseasesIntention to Treat AnalysisProspective StudieGrazoprevirItaly030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemalebusinessmedicine.drugHumanThe American journal of gastroenterology
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Knee arthroscopy and exercise versus exercise only for chronic patellofemoral pain syndrome: 5-year follow-up.

2011

Objective To study the long-term outcome of arthroscopy in patients with chronic patellofemoral pain syndrome (PFPS), the authors conducted a randomised controlled trial. The authors also investigated factors predicting the outcome in patients with PFPS. Methods Fifty-six patients with PFPS were randomised into two groups: an arthroscopy group (N=28), treated with knee arthroscopy and an 8-week home exercise programme, and a control group (N=28), treated with a similar 8-week home exercise programme only. The primary outcome was the Kujala score on pain and function at 5-year. Secondary outcomes were visual analogue scales (VASs) to assess activity-related symptoms. Results According to the…

AdultMalemedicine.medical_specialty5 year follow upPhysical Therapy Sports Therapy and Rehabilitationlaw.inventionArthroscopyYoung AdultRandomized controlled triallawmedicineHumansOrthopedics and Sports MedicineIn patientYoung adultta315Knee arthroscopyIntention-to-treat analysismedicine.diagnostic_testbusiness.industryArthroscopyGeneral Medicinemedicine.diseaseCombined Modality TherapyExercise TherapyIntention to Treat AnalysisTreatment OutcomePatellofemoral Pain SyndromeChronic DiseasePhysical therapyFemalebusinessPatellofemoral pain syndromeFollow-Up StudiesBritish journal of sports medicine
researchProduct

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

2021

BackgroundNo adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. MethodsWe conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks fo…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatment[SDV.CAN]Life Sciences [q-bio]/CancerKaplan-Meier EstimateAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyB7-H1 AntigenDisease-Free Survival03 medical and health sciences0302 clinical medicineDouble-Blind MethodStomach NeoplasmsInternal medicineMedicine and Health SciencesmedicineCarcinomaHumans030212 general & internal medicineEsophagusImmune Checkpoint InhibitorsNeoadjuvant therapyAgedAged 80 and overChemotherapybusiness.industryCancerChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseNeoadjuvant TherapyIntention to Treat Analysis3. Good healthNivolumabmedicine.anatomical_structureChemotherapy AdjuvantCarcinoma Squamous CellFemaleEsophagogastric JunctionNivolumabbusinessAdjuvantChemoradiotherapyNew England Journal of Medicine
researchProduct

Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial.

2011

Objective To evaluate the efficacy and safety of an intraoral electrostimulation device, consisting of stimulating electrodes, an electronic circuit, and a power source, in treating xerostomia. The device delivers electrostimulation through the oral mucosa to the lingual nerve in order to enhance the salivary reflex. Methods The device was tested on a sample of patients with xerostomia due to Sjogren's syndrome and other sicca conditions in a 2-stage prospective, randomized, multicenter trial. Stage I was a double-blind, crossover stage designed to compare the effects of the electrically active device with the sham device, each used for 1 month, and stage II was a 3-month open-label stage d…

AdultMalemedicine.medical_specialtyImmunologySettore MED/50 - Scienze Tecniche Mediche ApplicateElectric Stimulation TherapySeverity of Illness IndexXerostomialaw.inventionRandomized controlled trialQuality of lifestomatognathic systemRheumatologyDouble-Blind MethodlawSettore MED/28 - Malattie OdontostomatologicheMulticenter trialSeverity of illnessotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansPharmacology (medical)Prospective StudiesOral mucosaProspective cohort studyAgedxerostomia; dry mouth; salivary gland hypofunction; saliva; electrical stimulation; electrostimulation; Sjögren’s syndromeIntention-to-treat analysisToxicitybusiness.industryMouth MucosaMiddle AgedDry mouthSurgeryOral cavityIntention to Treat Analysisstomatognathic diseasesmedicine.anatomical_structureSjogren's SyndromeTreatment OutcomeAnesthesiaFemalemedicine.symptombusinessArthritis and rheumatism
researchProduct

Individual music therapy for depression: randomised controlled trial

2011

BackgroundMusic therapy has previously been found to be effective in the treatment of depression but the studies have been methodologically insufficient and lacking in clarity about the clinical model employed.AimsTo determine the efficacy of music therapy added to standard care compared with standard care only in the treatment of depression among working-age people.MethodParticipants (n= 79) with an ICD–10 diagnosis of depression were randomised to receive individual music therapy plus standard care (20 bi-weekly sessions) or standard care only, and followed up at baseline, at 3 months (after intervention) and at 6 months. Clinical measures included depression, anxiety, general functioning…

AdultMalemedicine.medical_specialtyTime FactorsMusic therapyAdolescentAnxietySeverity of Illness Indexlaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Randomized controlled triallawSeverity of illnessmedicineHumansAffective Symptoms030212 general & internal medicinePsychiatryMusic TherapyFinlandDepression (differential diagnoses)ta515Psychiatric Status Rating ScalesDepressive DisorderIntention-to-treat analysisOdds ratioMiddle Agedta3124Intention to Treat Analysis030227 psychiatryPsychiatry and Mental healthOutcome and Process Assessment Health Careta6131Quality of LifePhysical therapyPsychotherapy BriefAnxietyFemalemedicine.symptomPsychologyProgram EvaluationThe British Journal of Psychiatry
researchProduct